



Psychedelics Life Sciences Company

**Fighting Disorders of the
Brain and Nervous System with
Psychedelic Pharmaceuticals**

Corporate Presentation
October 2020



Pharmather Inc.

82 Richmond Street East, Toronto, ON, M5C 1P1 Canada

Tel: 1-888-846-3171 | info@pharmather.com | pharmather.com

Forward Looking Statements

This presentation of Newscope Capital Corporation (dbd Pharmather Inc.) (“Pharmather”) contains "forward-looking information", which may include, but is not limited to, statements with respect to anticipated business plans or strategies of Pharmather, the anticipated date of completion of research studies, the timing of any drug trials, the success of its clinical trials, the ability to enter into licenses, acquisitions or collaborations to enhance its drug development platform, the success of any such licenses, acquisitions or collaborations and the ability to use the information relating to, or obtain patents or other intellectual property protection on, data and clinical trials generated directly by Pharmather or through such licenses, acquisitions or collaborations, and the success or stage of development of discoveries or medicines. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Pharmather to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Pharmather’s management’s discussion and analysis for the period of August 30, 2020 (“MD&A”), dated October 1, 2020, which is available on Pharmather’s profile at www.sedar.com. Forward-looking statements contained herein are made as of the date of this presentation and Pharmather disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

Key Takeaways

1

Psychedelics life sciences company

2

Target large unmet medical needs with psychedelic pharmaceuticals

3

Unique AI discovery, development and delivery platforms

4

Robust pipeline for disorders of the brain and nervous system

5

Broad intellectual property portfolio

6

Experienced team and world-class partnerships

7

Undervalued compared to peers

8


Near-term value creation catalysts

Current Landscape

Psychedelic Pharmaceuticals Renaissance

- ✓ FDA approved Ketamine (Spravato®) for treatment-resistant depression (TRD) and major depressive disorder
- ✓ FDA designated both MDMA-assisted psychotherapy for PTSD and psilocybin for TRD as 'breakthrough therapies'

Popular Psychedelics



World-Renowned Research Institutes



Industry Adopters



About Us

Developing Psychedelic Pharmaceuticals

Mission

Discover and develop new uses of psychedelic pharmaceuticals for disorders of the brain and nervous system

Focus


Develop psychedelics for FDA approval by repurposing with AI and combining with FDA approved drugs and novel delivery systems

Strategy

Reduce cost, time, development risk and leverage FDA incentives such as 505(b)(2), orphan and fast-track designations

Our Product Pipeline

Psychedelic Focused FDA Clinical Developments



Catalysts

Over Next 4 Months

- ✓ FDA IND acceptance – Ketamine for Parkinson’s Disease
- ✓ FDA IND acceptance – Ketamine for Depression
- ✓ FDA Orphan designation – Ketamine for Parkinson’s Disease
- ✓ Research results – Psilocybin for treatment of TBI
- ✓ Research results – Psilocybin for treatment of Stroke
- ✓ Research results – Microneedle Psilocybin and Ketamine
- ✓ panaceAI™ results - Discoveries of new uses of psychedelics and combinations with FDA approved drugs


Over Next 12 Months

- ✓ FDA Phase 2 study results – Ketamine for Parkinson’s Disease
- ✓ FDA Phase 2 study interim results – Ketamine for Depression
- ✓ Initiate FDA clinical study – Microneedle Psilocybin and Ketamine
- ✓ Initiate FDA clinical study – Psilocybin for TBI
- ✓ Initiate FDA clinical study – Psilocybin for Stroke
- ✓ FDA Orphan designation – Psilocybin for TBI
- ✓ FDA Orphan designation – Psilocybin for Stroke
- ✓ Partnerships (i.e. licenses, JVs) with panaceAI™
- ✓ Listing on U.S. stock exchanges (OTCQB and Nasdaq)

Our Market Opportunity


\$100 Billion Market Potential

Initial Targets



USA prevalence statistics


Future Targets



.....and more!


Our Proprietary Platforms

Discovery




Artificial Intelligence for new uses of psychedelics and combinations with FDA drugs

Development



R&D in combining psychedelics with FDA approved drugs


Delivery




Novel microneedle delivery system for psychedelics

Discovery: panaceAI™ repurposing with AI

De-risking Pathway to Clinical Trials and Partnerships





Development: Novel Combinations



Delivery: Microneedle patch

Delivering Psychedelic Pharmaceuticals



Actual figures of microneedle path (a) Optical image (OI) no drug (b) OI with drug (c) OI with no drug close up (d) Fluorescent microscope of drug loaded close up

- ✓ Biocompatible and biodegradable gelatin methacryloyl (GelMA) composite
- ✓ Penetrates skin and mucosa, flexible drug load capacity and combinations, controlled-release
- ✓ Improved delivery over oral, injection, topical and nasal delivery methods
- ✓ Able to deliver psychedelics, small molecules, biomacromolecules and nanoparticles
- ✓ Opportunities in CNS, pain, cancer, wounds and infectious diseases

Ketamine: FDA Approved Psychedelic

Massive Potential *ALSO* Significant Limitations

Potent anesthetic



Powerful pain reliver



Effective in treatment resistant depression



Rapid onset of action



Reduces suicidal thoughts



Cognitive impairment

Hallucinations, Blurred Vision, Memory Loss, Nausea, Dizziness



Abuse liability, Tolerance



Increased Blood Pressure, Interstitial Cystitis



Liver & Bladder Injury



Administered at clinic by healthcare professional

Our Solution to Ketamine

Combining Ketamine with FDA Approved Drug

Effective in depression models



Enhances efficacy of Ketamine



Reduces psychotomimetic side effects ie. amnesia, social & motor dysfunctions



Reduces suicidal thoughts



Reduces addiction/abuse liability



Enables 505(B)(2) FDA regulatory pathway:

- Lower risk and cost
- Accelerated development
- Market exclusivity

Cognitive impairment
Hallucinations, Blurred Vision, Memory Loss, Nausea, Dizziness

Abuse liability, Tolerance

Increased Blood Pressure, Interstitial Cystitis

Liver and Bladder Injury

Administered only by healthcare professional

Depression Overview

Prevalence

+260M

Patients globally

+17M

Patients in the U.S.

Unmet Need

63% of major depressive disorder patients have inadequate response to initial therapy and second line therapy, respectively

Treatments

Oral anti-depressants and atypical antipsychotics have significant side effects

i.e. Anxiety, sexual dysfunction, insomnia, dizziness, nausea and vomiting, headache, sweating, weight gain, stomach pain, tiredness, tardive dyskinesia, nervousness, restlessness



Parkinson's Disease Overview

Prevalence

10M

Patients globally

1M

Patients in the U.S.

Unmet Need

No cure and management of the disease consists of the use of treatments that attempt to control motor symptoms primarily through dopaminergic mechanisms

Treatments

Gold standard for motor symptoms is levodopa + carbidopa where benefits wear off more quickly and patients experience motor fluctuations through the day



Our Solution: Ketamine

Human Clinical Evidence | Exclusive License from U of Arizona



UA Clinical Trial to Repurpose Ketamine for Parkinson's Patients

Jul 18, 2018

The best-known treatment for Parkinson's disease isn't perfect. Named levodopa, the drug can treat the stiffness and slowness of movement associated with the debilitating disease.

"The problem is levodopa works great for a few years — we call that the 'honeymoon' period — but then you start getting these side effects," says **Scott Sherman, MD, PhD**, a neurologist at the University of Arizona College of Medicine — Tucson.

Forty percent of patients on levodopa eventually will experience dyskinesia — uncontrollable and involuntary movements of the arms, legs, head or entire body. Severity can range from small, fidget-like motions to larger continuous bursts of movement.

Unless patients stop levodopa treatment altogether, these movements do not go away.

Now, UA researchers will repurpose ketamine, a drug currently used to treat pain and depression, to try to reduce and control these involuntary movements brought on by levodopa.



Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias

Scott J. Sherman^a Miguel Estevez^b Ari B. Magill^a Torsten Falk^a

<https://pubmed.ncbi.nlm.nih.gov/27293405/>

Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model

Mitchell J. Bartlett¹, Ria M. Joseph¹, Lindsey M. LePoidevin¹, Kate L. Parent², Nicholas D. Laude², Levi B. Lazarus², Michael L. Heien², Miguel Estevez³, Scott J. Sherman¹, and Torsten Falk^{1,*}

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728020/>

<https://pubmed.ncbi.nlm.nih.gov/32717354/>

- ✓ Robust data of tolerability, safety and long-term reduction of abnormal involuntary movements
- ✓ Reduces L-DOPA-induced dyskinesia (LID), improve on time, and reduce depression in Parkinson's patients
- ✓ 'Chemical deep brain stimulation', by desynchronizing hypersynchronous oscillatory brain activity
- ✓ Low-dose sub-anesthetic ketamine infusion could be novel long-term treatment modality to reduce LID
- ✓ Expansion into pain and depression in PD

Intellectual Property

Robust IP Portfolio of Patent Coverage into 2040

panaceAI™

Serial No. 63/011,471

Method of Identifying New Medical Indications for Pharmaceuticals

Microneedle Delivery System

Serial No. PCT/US19/58333

Biodegradable gelatine methacryloyl microneedles for transdermal drug delivery

Serial No. 62/946,709

Microneedle patch with detachable hybrid microneedle depot for localized delivery of stem cells

Drug Combinations

Undisclosed (Internal research, Term sheet)

Method and composition for decreasing the side effects and addictive disorder of ketamine and psilocybin

Psilocybin and Ketamine

Serial No. 15/574,346

Compositions and Methods for Treating Motor Disorders

Serial No. 63/011,493

Use of Psilocybin in the Treatment of Neurological Brain Injury

Multiple provisional patent applications filed from 2015-2020

Key Relationships



**panaceAI™ Research
and Development**



**Exclusive License for Ketamine in
Motor Disorders (PD, Pain, Depression)**



**Psilocybin and Ketamine
Research and Development**



**Drug Development,
Clinical and Regulatory Affairs**

Team

AI, Drug Development and Capital Markets Experience

Management and Advisors

Fabio Chianelli

Chairman & CEO

- Past Founder, CEO, President of Revive Therapeutics Ltd.

Carmelo Marrelli, CA

Chief Financial Officer

- CFO of multiple TSX and CSE companies

Dr. Joga Gobburu, PhD

Scientific, Clinical & Regulatory Advisor

- Director of Pharmacometrics at FDA
- University of Maryland, Professor of Pharmacy Practice and Science and Director, Center for Translational Medicine

Dr. Phedias Diamandis, MD, PhD

Machine Learning & AI Advisor

- Machine Learning/AI, Princess Margaret Neuropathologist

Board of Directors

Fabio Chianelli, Chairman & CEO

- Past Founder, CEO, President of Revive Therapeutics Ltd.

Dr. Bev Incledon, Director

- EVP and Chief Scientific Officer, Ironshore Pharma
- +28 years drug discovery & development experience

Christian Scovenna, Director

- +12 years capital markets experience

Carlo Sansalone, Director

- Past Director of Revive Therapeutics Ltd.

Peer Comparison

Market Caps

as of October 9, 2020



\$1.20 Billion

Phase 2b | Psilocybin | TRD



\$385 Million

Phase 2 | LSD / Ibogaine | CNS



\$13 Million

*Phase 2 | Ketamine / Psilocybin | PD, TRD, TBI

* Initiate < 6 months

Financial Snapshot



Newscope Capital Corporation
(d/b/a Pharmather)

\$0.195

Share Price

Figures as of October 9, 2020

\$13M

Market Cap

65,376,000

I/O Common Shares

1,802,200

Warrants

4,875,000

Stock Options